Ha Tay Pharmaceutical JSC (HNX:DHT)
Vietnam · Delayed Price · Currency is VND 84,000
-2,600 (-3.00%)
At close: Sep 8, 2025
Ha Tay Pharmaceutical JSC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 2,157,264 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 | 2,006,475 | Upgrade | |
Revenue Growth (YoY) | 10.49% | 4.35% | 8.81% | 14.17% | -19.79% | -1.75% | Upgrade |
Cost of Revenue | 1,931,015 | 1,866,534 | 1,795,972 | 1,650,138 | 1,455,342 | 1,767,422 | Upgrade |
Gross Profit | 226,249 | 219,818 | 203,331 | 187,256 | 154,022 | 239,053 | Upgrade |
Selling, General & Admin | 154,774 | 143,306 | 104,115 | 84,806 | 91,953 | 129,633 | Upgrade |
Operating Expenses | 154,774 | 143,306 | 104,115 | 84,806 | 91,953 | 129,633 | Upgrade |
Operating Income | 71,475 | 76,513 | 99,216 | 102,450 | 62,070 | 109,420 | Upgrade |
Interest Expense | -14,147 | -13,449 | -20,099 | -14,304 | -13,993 | -13,323 | Upgrade |
Interest & Investment Income | 26,646 | 19,544 | 19,614 | 25,120 | 30,725 | 14,355 | Upgrade |
Earnings From Equity Investments | 9,166 | 6,756 | 4,171 | 2,971 | 1,996 | 1,363 | Upgrade |
Other Non Operating Income (Expenses) | 5,066 | 5,858 | 7,442 | 6,986 | 8,715 | 8,721 | Upgrade |
EBT Excluding Unusual Items | 98,205 | 95,222 | 110,344 | 123,224 | 89,513 | 120,536 | Upgrade |
Pretax Income | 98,205 | 95,222 | 110,344 | 123,224 | 89,513 | 120,536 | Upgrade |
Income Tax Expense | 20,274 | 20,028 | 21,382 | 24,259 | 18,123 | 24,427 | Upgrade |
Earnings From Continuing Operations | 77,931 | 75,194 | 88,961 | 98,964 | 71,390 | 96,109 | Upgrade |
Minority Interest in Earnings | -4,995 | -3,422 | -3,906 | -3,753 | -3,444 | -4,061 | Upgrade |
Net Income | 72,936 | 71,772 | 85,056 | 95,211 | 67,946 | 92,047 | Upgrade |
Net Income to Common | 72,936 | 71,772 | 85,056 | 95,211 | 67,946 | 92,047 | Upgrade |
Net Income Growth | 9.12% | -15.62% | -10.67% | 40.13% | -26.18% | 6.74% | Upgrade |
Shares Outstanding (Basic) | 82 | 82 | 51 | - | - | - | Upgrade |
Shares Outstanding (Diluted) | 82 | 82 | 51 | - | - | - | Upgrade |
Shares Change (YoY) | - | 62.83% | - | - | - | - | Upgrade |
EPS (Basic) | 885.79 | 871.65 | 1681.99 | - | - | - | Upgrade |
EPS (Diluted) | 885.79 | 871.65 | 1681.99 | - | - | - | Upgrade |
EPS Growth | - | -48.18% | - | - | - | - | Upgrade |
Free Cash Flow | -18,547 | -115,173 | -95,725 | -286,024 | -83,817 | 5,466 | Upgrade |
Free Cash Flow Per Share | -225.25 | -1398.74 | -1892.97 | - | - | - | Upgrade |
Dividend Per Share | - | - | - | - | 357.143 | - | Upgrade |
Gross Margin | 10.49% | 10.54% | 10.17% | 10.19% | 9.57% | 11.91% | Upgrade |
Operating Margin | 3.31% | 3.67% | 4.96% | 5.58% | 3.86% | 5.45% | Upgrade |
Profit Margin | 3.38% | 3.44% | 4.25% | 5.18% | 4.22% | 4.59% | Upgrade |
Free Cash Flow Margin | -0.86% | -5.52% | -4.79% | -15.57% | -5.21% | 0.27% | Upgrade |
EBITDA | 94,549 | 96,993 | 116,294 | 119,898 | 78,721 | 122,680 | Upgrade |
EBITDA Margin | 4.38% | 4.65% | 5.82% | 6.53% | 4.89% | 6.11% | Upgrade |
D&A For EBITDA | 23,074 | 20,481 | 17,078 | 17,448 | 16,651 | 13,259 | Upgrade |
EBIT | 71,475 | 76,513 | 99,216 | 102,450 | 62,070 | 109,420 | Upgrade |
EBIT Margin | 3.31% | 3.67% | 4.96% | 5.58% | 3.86% | 5.45% | Upgrade |
Effective Tax Rate | 20.64% | 21.03% | 19.38% | 19.69% | 20.25% | 20.27% | Upgrade |
Revenue as Reported | 2,157,264 | 2,086,353 | 1,999,304 | 1,837,395 | 1,609,364 | 2,006,475 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.